CCL21 and metabolic disease: In addition to transporter inhibitors directly targeting SLC proteins for the treatment of metabolic diseases, researchers and clinicians have found that SLC transporters can also be used as probes for disease diagnosis and to indirectly enhance drug selectivity or efficacy through SLC transporters.